Chronic pain, by definition, is difficult to manage, but a new study by UCSF scientists shows how a cell therapy might one day be used not only to quell some common types of persistent and difficult-to-treat pain, but also to cure the conditions that give rise to them.
The researchers, working with mice, focused on treating chronic pain that arises from nerve injury — so-called neuropathic pain.
In their study, published in the May 24, 2012 issue of Neuron, the scientists transplanted immature embryonic nerve cells that arise in the brain during development and used them to make up for a
MENLO PARK, Calif., August 18, 2009 – Geron Corporation announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency’s review of new nonclinical animal study data submitted by the company. A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial or to suspend an ongoing trial.
Since filing the IND, Geron has been undertaking studies to enable dose escalation of its spinal cord injury product, and has been investigating application
UC San Diego scientists have dramatically improved the success rate of genetically modifying human embryonic stem cells. This advance brings the promise of better treatment of genetic diseases.
The new approach works in 20 percent of embryonic stem cells, compared to less than 1 percent treated with standard methods, said Yang Xu, a UCSD professor of biology, who led the study, assisted by Hoseok Song and Sun-Ku Chung, postdoctoral fellows in his lab.
The study was published Thursday in the journal Cell Stem Cell.
Some genetic diseases can’t be studied adequately in animals, Xu said, so the ability to produce human cells
A team of researchers has brought the end of diabetes closer to reality by announcing a new breakthrough that could lead directly to a cure and not just a treatment for the disease.
The scientists discovered a protein that activates the maturation process in vitro, overcoming this longstanding obstacle in diabetes therapy development.
“In a dish, with this one switch, it’s possible to produce a functional human beta cell that’s responding almost as well as the natural thing,” says senior author Ronald Evans of the Salk Institute. “This has been a major blockade, and overcoming it has been a major challenge
If we are to produce sustainable and healthy food for the global population of nine billion people that is projected in 2050, then we must think along completely new lines.
Imagine this: With a clear conscience you sink your teeth into a juicy and tasty hamburger. No animal has been slaughtered to deliver the meat, no new forest felled to make way for animal feed, no bovine methane burps have affected the climate and no slurry has been released into the environment. The hamburger also has a satisfyingly low fat content and the fat consists only of fatty acids that